News & Updates

Chronic air pollution exposure ups MAFLD risk

01 Jan 2022

Prolonged exposure to ambient air levels of particulate matter ≤1 µm (PM1), ≤2.5 µm (PM2.5), and ≤10 µm (PM10), as well as of nitrogen dioxide (NO2), appears to aggravate the likelihood of metabolic dysfunction-associated fatty liver disease (MAFLD), a recent study has found.

Chronic air pollution exposure ups MAFLD risk

01 Jan 2022

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

30 Dec 2021

In people with type 2 diabetes, liver fibrosis, measured according to indices, may be associated with diabetic peripheral neuropathy (DPN), a recent study has found.

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

30 Dec 2021

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

25 Dec 2021

In patients with decompensated cirrhosis, high urinary levels of the liver fatty acid-binding protein (L-FABP) appear to predict the risk of mortality and of acute-on-chronic liver failure, a recent study has found.

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

25 Dec 2021

Drinking water may reduce NAFLD prevalence in men

22 Dec 2021

Higher intake of plain water appears to suppress newly diagnosed nonalcoholic fatty liver disease (NAFLD) among men but not women, a recent study has found.

Drinking water may reduce NAFLD prevalence in men

22 Dec 2021

New algorithm predicts HCC risk in compensated advanced chronic liver disease

19 Dec 2021

A novel algorithm using post-treatment age, albumin, and liver stiffness measurement (LSM), among other parameters, can accurately stratify patients with compensated advanced chronic liver disease (cACLD) according to their de novo hepatocellular carcinoma (HCC) risk, a new study shows.

New algorithm predicts HCC risk in compensated advanced chronic liver disease

19 Dec 2021

NAFLD prevalent in IBD patients

16 Dec 2021 by

The incidence of nonalcoholic fatty liver disease (NAFLD) is high among individuals with inflammatory bowel disease (IBD), according to data presented at AIBD 2021.

NAFLD prevalent in IBD patients

16 Dec 2021

Study offers clues on which patients may safely stop HBV therapy

15 Dec 2021 by

Think twice before withdrawing HBV treatment. Not all patients can safely discontinue nucleos(t)ide analogue (NA) therapy as shown in the retrospective RETRACT-B study of patients from Europe, North America, and Asia.

Study offers clues on which patients may safely stop HBV therapy

15 Dec 2021

Increased serum iron may hint at HCC risk in NAFLD patients

07 Dec 2021 by

Increased serum iron or transferrin saturation levels in individuals with non-alcoholic fatty liver disease (NAFLD) may point to an increased risk of hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting Digital Experience™.

Increased serum iron may hint at HCC risk in NAFLD patients

07 Dec 2021

Switching to TAF helps improve virologic response in HBV patients in real world

06 Dec 2021 by

Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.

Switching to TAF helps improve virologic response in HBV patients in real world

06 Dec 2021

Interim findings boost therapeutic potential of lanifibranor for NASH

06 Dec 2021 by

The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.

Interim findings boost therapeutic potential of lanifibranor for NASH

06 Dec 2021

News & Updates

Filter by Specialty:

Specialty:

Chronic air pollution exposure ups MAFLD risk

Chronic air pollution exposure ups MAFLD risk

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

Indices of liver fibrosis tied to diabetic peripheral neuropathy in type 2 diabetes

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

Urinary L-FABP predicts 3-month mortality, complications in decompensated cirrhosis

Drinking water may reduce NAFLD prevalence in men

Drinking water may reduce NAFLD prevalence in men

New algorithm predicts HCC risk in compensated advanced chronic liver disease

New algorithm predicts HCC risk in compensated advanced chronic liver disease

NAFLD prevalent in IBD patients

NAFLD prevalent in IBD patients

Study offers clues on which patients may safely stop HBV therapy

Study offers clues on which patients may safely stop HBV therapy

Increased serum iron may hint at HCC risk in NAFLD patients

Increased serum iron may hint at HCC risk in NAFLD patients

Switching to TAF helps improve virologic response in HBV patients in real world

Switching to TAF helps improve virologic response in HBV patients in real world

Interim findings boost therapeutic potential of lanifibranor for NASH

Interim findings boost therapeutic potential of lanifibranor for NASH